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OBJECTIVES: The aim of our study was to investigate the impact of typical and atypical antipsychotic drugs on leptin
concentration in blood and changes in the receptor expression in the hypothalamus of male Wistar rats.
METHODS: From the age of 13 to 18 weeks, three groups of 20 animals were fed an average dose of 3.5 ¡ 0.03
mg/ kg body weight (BW) haloperidol; 30.6 ¡ 0.22 mg/kg BW clozapine; or 14.9 ¡ 0.13 mg/kg BW ziprasidone in
ground food pellets containing 15% fat. Twenty control animals received no drugs. Blood samples were taken at
week 14, 16, and 19. Locomotor activity and exploratory behavior were measured using the alcove test at weeks 15
and 17. The expression of the hypothalamic leptin receptor in rat brains was determined by using a Western blot.
RESULTS: Rats medicated with haloperidol and ziprasidone showed a significantly decreased percentage weight
gain and food consumption. We observed no differences in the alcove test, but locomotor activity was significantly
reduced in the haloperidol group. Except for rats in the clozapine and ziprasidone groups, after 2 weeks of drug
application, we found no changes in the leptin blood concentrations among the four groups or animals within each
group. Moreover, we did not find specific differences in hypothalamic leptin receptor expression among the groups.
CONCLUSION: We concluded that in male Wistar rats during this treatment period, the tested drugs did not act
directly on the leptin regulatory system. We recommend further studies using long-term treatment of different rat
strains.
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INTRODUCTION
Antipsychotic drug medication is an important therapeutic
option for the treatment of patients suffering from schizo-
phrenia and other psychoses. Based on their mechanism of
action, antipsychotics are classified as either typical or
atypical drugs. Medication with typical antipsychotic drugs
(haloperidol is applied most frequently) can be accompanied
by severe extrapyramidal side effects. Atypical antipsychotic
drugs like clozapine usually cause no extrapyramidal side
effects but can lead to unwanted weight gain.1,2 Interestingly,
ziprasidone, a newer atypical antipsychotic drug, is not
linked with weight gain.3 As increased body weight may be
associated with an increase in blood leptin concentration,4
researchers proposed that an impaired leptin secretion or
signalling might play a role in antipsychotic-induced weight
gain.
Adiposity and weight gain are closely associated with
severe health problems, including hypertension, type II
diabetes, and coronary disease. Moreover, weight gain under
antipsychotic treatment may reduce compliance and cause
patients to abandon the medication. This endangers treat-
ment success and causes a risk of critical deterioration of the
psychiatric condition. Therefore, the availability of antipsy-
chotic drugs without the side effect of weight increase
appears to be fundamental for effective and cost-efficient
treatment of schizophrenia. The mechanisms underlying
antipsychotic-induced weight gain, however, are poorly
understood. Plausible explanations include reduced physical
activity, metabolic changes resulting in reduced calorie burn-
off, stronger appetite resulting in increased food intake,5,6
and differences in receptor binding profiles.7
In the complex physiological network regulating food
intake, energy expenditure, and fat storage, researchers
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have found that leptin plays a key role. Leptin, a
polypeptide product of the obese (OB) gene, is secreted by
adipocytes. Its expression and secretion shows a strong
positive correlation with body fat mass and adipocyte number
and size.8 Leptin, together with other hormones, including
glucocorticoids, amylin, and insulin, plays an important role
in regulating food intake, energy expenditure, body weight
homeostasis,9 reproduction function, and neuroendocrine
responses.10 The lack of leptin results in hormonal and
metabolic alterations and a dramatic increase in body
weight.11 One of the primary tasks of leptin is sending
information to the central nervous system – especially
hypothalamic areas – about the amount of energy stored in
the adipose tissue. In the brain, leptin interacts with the Ob-R
receptor found in both rodents and humans. The leptin
receptor is a class I cytokine receptor, a single-membrane-
spanning protein that has several isoforms due to alternative
splicing.12 The short form Ob-Ra and the long form Ob-Rb are
both abundantly expressed in the hypothalamus.
Haloperidol, which produces little or no weight gain, acts
primarily on the dopamine D2 receptors, whereas clozapine
has a high affinity with the histamine H1 and the serotonin
5-HT2C receptors. Both H1 and 5-HT2C receptors are
implicated in the control of food intake and body weight.13
Furthermore, the histamine H3 receptor seems to play a key
role in the regulation of food intake and hunger by
inhibiting other neurotransmitters, such as serotonin,
noradrenaline, and acetylcholine, and by controlling the
synthesis and release of histamine.14 Studies have shown
increased leptin concentrations in psychiatric patients
treated with clozapine or conventional antipsychotics15
and also in noncompliant patients, but not in antipsycho-
tic-naı¨ve, first-episode schizophrenic patients.16 Haupt et
al.17 detected no differences in the plasma leptin concentra-
tions of patients medicated with antipsychotic drugs and
healthy controls. However, Thakore et al.18 showed that
drug-naive and drug-free patients with schizophrenia
exhibit increased intra-abdominal fat and that people with
schizophrenia appear to be overweight more often than
those in the general population.19
Experimental studies on rodents can help researchers to
understand the mechanisms underlying antipsychotic-
induced metabolic changes. Numerous studies of both
classical and atypical antipsychotic drugs have demon-
strated changes in body weight, food consumption, or body
fat composition associated with the release of leptin.
Increasing serum leptin levels in male Sprague Dawley rats
after long-term treatment using haloperidol and olanzapine
added to food were substantiated in a study by Minet-
Ringuet et al.20 Chronic clozapine application in female
Wistar rats showed a negative correlation between serum
leptin levels and the given doses (i.p.).21 In our study, we
aimed to clarify the effect of typical and atypical anti-
psychotic drugs on blood leptin secretion and hypothalamic
leptin receptor expression. These results were correlated
with weight gain and food and water consumption after a 6-
week period of selective treatment with haloperidol,
clozapine, or ziprasidone mixed with food.
METHODS
Animals and housing conditions
All experiments were carried out in accordance with the
local laws governing animal experimentation and approved
by Bezirksregierung Du¨sseldorf authorities. On postnatal
day 21 (PD 21), male pups of Wistar rats (outbreed strain,
animal facility Du¨sseldorf, Heinrich-Heine-University of
Du¨sseldorf) were removed from their mothers and were
individually housed on PD 85 with free access to water and
dry, ground food pellets containing 15% fat. They were
maintained on a 12:12 light/dark cycle (lights off at 20.00 h)
at a temperature of 21 C˚ and 60% humidity. To limit the
possible impact of individual weight gain of the test
animals, the rats derived from litters with identical pup
numbers, so each group was equally composed of rats with
different parentage.
Preliminary dose test
Based on the results of Kapur et al.,22 which showed that
the current dosing of haloperidol in animal studies is
inappropriately low in chronic dosing studies, we tested
3 different daily doses of each antipsychotic drug added to
ground food pellets: 2, 5, and 8 mg haloperidol (Haloneural,
Hexal, Germany)/ kg body weight (BW); 20, 40, and 50 mg
clozapine (Leponex, Novartis, Germany)/ kg BW; and 10,
20, and 25 mg ziprasidone (Zeldox, Pfizer, Germany)/ kg
BW. Each dose was tested in 3 animals beginning at the age
of 12 weeks. Weight gain and food consumption in g per
100 g BW were measured during a 2-week period, and the
serum level of haloperidol, clozapine, and N-desmethylclo-
zapine were determined by HPLC in ng/ml.
Assessment of food and water consumption
Starting at week 11 (PD 71), the animals were weighed
twice per week (a = first weighing on Tuesday and
b = second weighing on Friday), and their weekly water
consumption was calculated. Each animal’s food consump-
tion was measured each day and averaged for a week,
including the loss of ground pellets in the litter. Based on
the preliminary dose studies starting at week 13 (PD 85),
each of the 20 animals in a trial group received an average
daily dose of 3.5 ¡ 0.03 mg/kg BW haloperidol, 30.6 ¡
0.22 mg/kg BW clozapine, or 14.9 ¡ 0.13 mg/kg ziprasi-
done in a measured quantity of ground pellets. Serum levels
of haloperidol and clozapine by HPLC showed that this
route of administration leads to pharmacologically active
plasma levels. The control group (20 animals) was fed only
ground pellets.
Assessment of serum leptin levels
On PD 96 (week 14) and PD 110 (week 16), blood samples
were taken from the retro-orbital plexus of anesthetised
animals with 150 mm glass Pasteur pipettes (Brand,
Germany).
The blood samples were centrifuged, and the leptin blood
serum level was determined by using a rat leptin assay kit
(IBL, Japan) in ng/ml. On PD 127 (week 19), the animals
were sacrificed by CO2 inhalation, and their blood was
sampled by cardiac puncture. The brains were removed and
immediately frozen in 2-methylbutane (Merck, Germany),
cooled down by liquid nitrogen, and stored at -80 C˚. The
serum levels of leptin in the heart blood were determined
using a rat leptin assay kit (IBL, Japan) in ng/ml.
Additionally, the serum levels of haloperidol and clozapine
(clozapine and N-desmethylclozapine) in the heart blood
were analyzed using HPLC in ng/ml. Ziprasidone was
not measurable since an HPLC method has not been
established.
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Horizontal locomotor activity and alcove test
Around week 11 and 12, the animals were habituated to
the experimental setup. Locomotor activity under antipsy-
chotic drug medication was measured compared to that of
non-treated controls using an open field activity test in a
standard box (40 6 40 6 30 cm). Animal movement was
restricted to the square acrylic inner cage that was closed
with a perforated lid. On PD 102 (week 15) and PD 116
(week 17), respectively, the animals were individually
placed into the center of the field and observed for 20 min
in the dark. Locomotion was assessed automatically using
photocells. In the alcove test, which is a refined open field
exploratory test,23 the rats were individually placed into a
small dark start box connected to a brightly-lit open field by
a guillotine door. The door of the box was opened and the
latency to leave the box was measured. Each trial ended
after 2 min and was repeated after 30 min. The scores of the
two tests were totalled.
Semiquantitative detection of the leptin receptor
Hypothalami of the brains, which were frozen and stored
at -80 C˚, were dissected, weighed, and homogenized in
0.25 ml ice-cold lysis buffer24 (50 mM Hepes pH 7,9; 10%
glycerol; 1 mM EDTA; 1 MM sodium pyrophosphate; 1 mM
sodium fluoride; 1 mM sodium vanadate; 1 mM PMSF;
containing a proteinase inhibitor, diluted 1:50, Sigma P
8340). Nonidet P-40 and Triton X-100 were added to a final
concentration of 1%. After 30 min on ice, the homogenates
were centrifuged at 4 C˚ at 13000 U¨ for 10 min. Proteins in
the supernatant were precipitated with A/G Plus-Agarose
(Santa Cruz Biotechnology, sc-2003) following the manu-
facturer’s specifications. The precipitates were centrifuged
after 10 min on ice at 13000 U¨ for 10 min at 4 C˚. The
supernatant was discarded and the sediment resolved in an
SDS buffer (0.005 DTT and 0.01 DTE resolved in 50 ml
distilled water and 450 ml 25% SDS diluted 1:6 in 0.05 M Tris-
HCl pH 8.8). The proteins were stored at -80 C˚. The protein
content of each sample was determined. For a Western blot
analysis, 30 mg protein were resolved by SDS-PAGE (7.5%
polyacrylamide in the separating gel) and transferred to a
PVDF membrane (Invitrolon PVDF 0.45 mm pore size,
Invitrogen, Carlsbad USA). Membranes were incubated in
TBS-T with 7.5% nonfat milk overnight at 4 C˚ followed by
2 h at room temperature with mouse monoclonal OB-R
antibody (diluted 1:400, Ob-R B-3; Santa Cruz Biotechno-
logy), which detects the short and long isoforms of the
receptor, and goat polyclonal actin antibody (1:800, Akt 1 C-
20; Santa Cruz Biotechnology). To identify immunoreactive
bands, membranes were subsequently incubated with HRP-
conjugated secondary antibodies (goat anti-mouse HRP IgG
and donkey anti-goat HRP IgG, respectively; diluted 1:5000
for detection of Ob-R and 1:10000 for detection of actin 1,
Santa Cruz Biotechnology). Signals were visualized using
a chemiluminescence detection kit (Santa Cruz Biotech-
nology) on Kodak BioMax Light film (Kodak Industries,
Chalon-sur-Saone, France). Resultant autoradiographs were
quantified by densitometry using Gene Snap and Gene tools
software (Syngene, Synoptics Ltd, United Kingdom).
Statistical analysis
All data are presented as mean ¡ SEM. The data were
analysed by two-way analyses of variance (ANOVA) with
GROUP as the between-group factor and WEEKS as the
repeated measures factor unless otherwise specified.
Posthoc tests with a-adjustment for repeated measurement
were carried out for single measurement points.
A bivariate correlation procedure using the Spearman-
Rho coefficient was carried out to test the relationship
between food consumption and the level of leptin in the
serum. We also tested the correlation between the level of
leptin in the heart blood and the animal’s weight before
death and the correlation between the level of leptin and the
amount of haloperidol and clozapine (clozapine and its
main metabolite N-desmethylclozapine) in the serum.
RESULTS
Preliminary dose test
We found an inverse dose / body weight gain correlation
of haloperidol and ziprasidone over 2 weeks with equal
results for food consumption. Animals fed with clozapine
showed the highest percentage of weight gain at 40 mg/ kg
BW with equal results for food consumption. But a one-way
ANOVA revealed no differences among the groups for body
weight gain and food consumption (all p $ 0.05).
At daily 2 mg/kg BW, haloperidol was not detectable in
the serum using HPLC. At 8 mg/kg BW, the side effects of
haloperidol, e.g., apathy, were very pronounced. Therefore,
we chose a daily dose of 5 mg/kg BW haloperidol. At
20 mg/kg BW, we detected only a low serum level of
clozapine, and its metabolite was not discernible. After
discovering a lower weight gain and food intake at 20 mg
and 50 mg clozapine, we decided to apply a daily dose of
40 mg/kg BW. We chose a daily dose of 20 mg/ kg BW of
Figure 1 - Timeframe of experimental setup. The male Wistar pups were removed from their mothers at PD 21, housed together, and
received ground pellets at this time. At week 11 and 12, the rats were weighed twice per week and were habituated to the activity and
alcove box. At week 13, the animals were medicated with haloperidol, clozapine, or ziprasidone (n = 20 for all groups) or were fed only
ground pellets (controls, n = 19). At week 12 and 14, blood was sampled. At weeks 15 and 17, activity and anxiety behavior was tested.
After 6 weeks of medication, the rats were anesthetized and their blood and brains were removed.
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ziprasidone (corresponding to a real weekly dose of
14.6 mg/kg BW), according to Pillai et al.25.
One finding of the preliminary dose test was the fact that
rats did not eat all of the allocated food each day. Therefore,
in the main trial, we calculated the real weekly dose and
averaged it over the test period. We calculated a mean dose
of 3.5 ¡ 0.03 mg haloperidol/ kg BW, 30.6 ¡ 0.22 mg
clozapine/ kg BW and 14.9¡ 0.13 mg ziprasidone/ kg BW.
Weight gain
Before starting the medication at the age of 11 and 12
weeks (data are not shown in Figure 1 because we refer to
the percentage body weight gain on the first weighing after
beginning the drug application), the animals’ weight
showed a significant difference over time, with weights
increasing for animals in all groups [F(3,165) = 699.3, p ,
0.00000], but there were no differences among the groups
[F(3,55) = 0.41, p = 0.75] and in the WEEKS*GROUP
[F(9,165) = 0.6, p = 0.8]. This indicates that the alterations
in body weight among the groups after week 12 resulted
from the antipsychotic medication.
We found a continuous weight gain in all four groups
over 6 weeks of drug application. The percentage increase in
weight referred to the first weighing after the onset of
antipsychotic medication and showed significant differ-
ences (Fig.1) for WEEKS [F(11,803) = 537.54, p , 0.00000],
WEEKS*GROUP [F(33,803) = 11.11, p , 0.00000], and
GROUP [F(3,73) = 14.6, p , 0.00000], with the highest
increase in the control group, followed by the clozapine and
the ziprasidone groups, and the lowest gain for the
haloperidol group.
Post-hoc tests revealed that the values of the haloperidol
group were significantly lower compared to controls (week
13b p = 0.001, week 15a p = 0.004, week 15b p = 0.0002, week
16a p = 0.0002, week 16b p = 0.0003, week 17a p = 0.0002,
week 17b p = 0.0001, week 18a p = 0.0002, and week 18b
p = 0.00003, respectively) and the clozapine group over all
weeks except for week 14 (week 13b p = 0.001, week 15b
p = 0.001, week 16a p = 0.001, week 16b p = 0.001, week 17a
p = 0.002, week 17b p = 0.001, week 18a p = 0.001, and week
18b p = 0.00008, respectively). Animals with ziprasidone
medication showed decreased body weight compared to the
control group from week 16 to week 18 (week 16a p = 0.003,
week 17a p = 0.001, week 17b p = 0.002, and week 18a
p = 0.004), but there were no differences between the
ziprasidone and the clozapine groups and between animals
Table 1 - Preliminary dose-finding test.
mg/kg BW/day % BW food intake/100g BW (g) drug serum level (ng/ml) N-desmethyl serum level (ng/ml)
2 haloperidol 20.8¡1.8 5.5¡0.3 0
5 18.9¡2.5 2 5.3¡0.4 2 65.8¡15.1 +
8 17.5¡0.8 5.1¡0.1 94.26¡12.1
20 clozapine 27.5¡0.6 5.7¡0.1 55.5¡9.6 0
40 28.8¡1.8 6.3¡0.4 75.5¡3.1 + 36.7¡7.7 +
50 26.1¡0.8 6.0¡0.2 110.6¡28.1 182.0¡26.1
10 ziprasidone 20.2¡0.9 5.4¡0.2
20 18.0¡1.8 2 5.3¡0.3 2
25 16.0¡1.2 5.0¡0.1
Q
Q
Q
Q Q
Q
Q
Figure 2 - Percentage weight gain of male Wistar rats: control (n = 19) and animals treated with haloperidol, clozapine, and
ziprasidone (n = 20 for all groups). All animals were weighed twice per week. Depicted is the weight after application of the
antipsychotic drugs from week 13 to week 18. No difference was found between the control and clozapine groups. The haloperidol-
treated animals gained less weight than the control and clozapine group directly after medication, whereas the ziprasidone group
gained less weight after 4 weeks of treatment than the control group with p# 0.004 considered significant.
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fed with ziprasidone and haloperidol. In the tested period,
no differences were detectable between the control and the
clozapine group (all p.0.004).
Food consumption
We averaged the food consumption of each day over a
week, based on 100 g BW (Fig.2), avoiding the influence of
the individual animals’ body weight on the results. Taking
into consideration the loss of ground pellets in the litter, we
subtracted the pellet parts, screened from the litter, from the
total weekly food quantity.
Statistical analysis revealed a significant decrease in food
consumption per 100 g BW over time [F(1,55) = 40.48, p ,
0.00000], but there were no differences for the
WEEKS*GROUP [F(3,55) = 2.01, p = 0.12] and GROUP
[F(3,55) = 0.66, p = 0.58] over the 2 weeks of testing before
antipsychotic application. Therefore, we concluded that the
differences among the four groups were a consequence of
drug medication.
After application of antipsychotic drugs, food consump-
tion continuously decreased over time [F(5,365) = 179.41,
p , 0.00000]. For WEEKS*GROUP [F(15,365) = 2.96,
p = 0.0002] and among the groups [F(3,73) = 9.72, p =
0.00002], we also found significant differences. The highest
food consumption level occurred in the control group, and
the lowest was in the haloperidol group. Posthoc tests
showed that at week 13 the groups did not differ with
reference to food consumption (all p. 0.008). From week 14
to 18, the food intake decreased significantly for the
haloperidol group compared with the control group (p =
0.004, p , 0.00000, p = 0.0003, p = 0.0002 and p = 0.00001,
respectively). At week 15 and 18, we also discovered
differences between the control and ziprasidone-treated
animals (p = 0.001 and p = 0.008, respectively). At weeks
15, 17, and 18, the level of food consumption of the rats with
haloperidol medication differed from those treated with
clozapine (p = 0.0004, p = 0.004 and p = 0.001,
respectively). We detected no such differences between the
clozapine and ziprasidone groups, between the control and
clozapine groups, and between the haloperidol and zipra-
sidone groups (all p . 0.008, accounting for the a-
adjustment).
Weekly water consumption
Water consumption was measured weekly. To avoid a
bias due to individual development of body weight over
time, water consumption was related to 100g BW (Fig. 3).
The one-way ANOVA showed no differences among the
groups at week 12 (p = 0.27). Thus, we concluded that
further differences in the course of the experiment between
the four groups were a consequence of antipsychotic
medication.
After the administration of the drugs, an ANOVA for
repeated measures showed no differences between
WEEKS*GROUP [F(15,170) = 1.26, p = 0.23]. Significant
differences were found from week 13 to week 18 (WEEKS
[F(5,170) = 22.74, p , 0.00000]) and among the drug groups
(GROUP [F(3,34) = 47.1, p , 0.00000]. Controls and
clozapine-medicated rats did not differ in drinking behavior
from week 13 to week 18 (all p . 0.008). In addition, the
behavior of the haloperidol-medicated animals was no
different than the behavior of rats medicated with ziprasi-
done (all p . 0.008). Significant differences were found
between controls and clozapine-medicated animals on the
one side and haloperidol- and ziprasidone-treated rats on
the other side during the course of the complete testing
period (p # 0.008 at all measuring points). Any correlation
between the real body weight and the water consumption
was not verifiable.
Figure 3 - Weekly food consumption based on 100 g BW of male
Wistar rats: control (n = 19) and animals treated with
haloperidol, clozapine, or ziprasidone (n = 20 for all groups).
All animals showed decreased food consumption from week 11
to week 18 with no differences before medication. Animals
under haloperidol medication ate less than the control and
clozapine groups after 1 week of application. Ziprasidone-
treated rats ate less than the controls after 3 week of medication.
We found no differences between the control and clozapine
groups with p# 0.008 considered significant.
Figure 4 - Weekly water consumption based on 100 g BW of male
Wistar rats: control (n = 19) and animals treated with
haloperidol, clozapine, or ziprasidone (n = 20 for all groups).
All animals showed slightly decreased water consumption from
week 11 to week 18 but no differences before medication.
Animals under haloperidol and ziprasidone medication drank
less than the control and clozapine groups after 1 week of
application. We found no differences between the control and
clozapine groups with p# 0.008 considered significant.
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Horizontal locomotor activity and alcove test
To examine the sedating impact of the neuroleptics, we
investigated locomotor activity and exploratory behavior in
the alcove test at weeks 15 and 17.
We found a decrease in the activity counts (Fig. 4A) from
week 15 to 17 [F(1,73) = 40.59, p , 0.00000] with high levels
in the control group and the group treated with clozapine,
followed by the group treated with ziprasidone, and an
unexpected low activity in the haloperidol group. The
activity counts for weeks 15 and 17 were significantly
different among the control, clozapine, and ziprasidone
groups (p = 0.005, p = 0.001 and p = 0.001, respectively),
but not in the haloperidol group (p = 0.18). We also found
differences for the WEEKS*GROUP [F(3,73) = 3.01, p =
0.035] and GROUP [F(3.73) = 12.54, p , 0.00000]. The
animals treated with haloperidol in week 15 (p = 0.00002 vs.
control group, p = 0.00007 vs. clozapine group and p =
0.001 vs. ziprasidone group) and week 17 (p = 0.001 vs.
control group, p = 0.004 vs. clozapine group and p =
0.02 vs. ziprasidone group) differed from the other groups,
whereas the controls and the animals treated with clozapine
and ziprasidone did not show differences.
In the alcove test, we found an increase in the latencies
(Fig. 4B) spent in the dark box from week 15 to 17 as
expected ([F(1,73) = 45.73, p , 0.00000]). Posthoc tests
revealed that the increase was not significant for all groups
(p = 0.007 for the control groups; p = 0.003 for the
haloperidol group, p = 0.005 for the clozapine group, and p
= 0.001 for the ziprasidone group). No differences were
found for the WEEKS*GROUP [F(3,73) = 0.21, p = 0.89]
and GROUPS [F(3,73) = 3.73, p = 0.05].
Blood leptin and drug concentration and leptin
receptor expression in the hypothalamus
We found a mean value of 18.3¡ 2.7 ng/ml haloperidol,
14.4 ¡ 2.2 ng/ml clozapine, and 134.0 ¡ 26.9 ng/ml N-
desmethylclozapine in the serum after 6 weeks of anti-
psychotic drug application.
Serum levels of leptin increased over time in the control,
clozapine, and ziprasidone groups, whereas the haloper-
idol-medicated group showed a maximum after 4 weeks of
drug application. Although the overall leptin concentration
in blood did not change over time (WEEKS [F(2,134) = 2.76,
p = 0.067]), differences were found for the WEEKS*GROUP
[F(6,134) = 2.18, p = 0.049] and GROUPS [F(3,67) = 5.31,
p = 0.002]. Posthoc tests showed significant differences
between the clozapine and ziprasidone groups two weeks
after medication (p = 0.005). All other groups yielded no
significant differences (p . 0.016).
To investigate the drug’s impact on leptin receptor
expression in the hypothalamus, we performed Western
blot and immunohistochemical experiments. No differences
in receptor expressions were discovered among the four
groups.
Correlation between food consumption, drug
quantity, weight before death and blood leptin
concentrations
We could not substantiate a significant correlation
between food consumption and leptin blood concentrations.
No correlation was detected between antipsychotic drug
levels and leptin concentration.
The bivariate correlation procedure showed a significant
positive effect (Sperman’s Rho correlation coefficient 0.567,
p = 0.01) between the weight of the animals (weight before
death) treated with haloperidol and leptin concentration.
No correlation was found in the other groups.
DISCUSSION
In this study, medication of male Wistar rats with
haloperidol, clozapine, and ziprasidone caused heteroge-
nous effects on weight gain, food and water intake, and
sedation compared to controls. The blood leptin concentra-
tion, however, was not different among the four groups, and
there were no age-dependent effects within the groups.
Moreover, there were no significant differences in the leptin
receptor expression in the hypothalami of medicated or
untreated animals.
Medication of rats with clozapine did not induce the
typical side effects known from observations in humans,
including weight gain,19 decreased physical activity,26 and
abnormal eating behavior like food craving or binge eating.6
However, we cannot exclude the fact that clozapine induced
body fat deposition in rats without increasing their body
Figure 5 - Horizontal locomotor activity behavior in the alcove test of male Wistar rats: control (n = 19) and animals treated with
haloperidol, clozapine, or ziprasidone (n = 20 for all groups). Haloperidol-medicated animals showed significantly reduced activity
with no habituation effect in contrast to the control, clozapine, and ziprasidone groups with p# 0.025. Rats medicated with
haloperidol and ziprasidon showed a higher latency in the alcove test and the results were not significantly higher than in the control
and clozapine groups.
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weight or metabolic abnormalities as described.20,21,27 To
clarify this point, in future studies of weight gain after
antipsychotic drug medication in rats, visceral white fat
depositions have to be determined.
In most rodent studies, antipsychotics were administered
by using daily gavage, drinking water,28 food, and intraper-
itoneal or subcutaneous injections. Drug administration by
food is the least-invasive application manner, reduces
handling stress, and allows the exact determination of food
and drug intake.29 The plasma half-life of neuroleptic drugs
lasts much longer in humans than in rodents. According to
Minet-Ringuet et al.20 it is plausible that by mixing
antipsychotics into the food, more consistent drug blood
levels are maintained, so this is a more promising approach
to model drug application in the human.
Weight gain, food and water consumption
The observed effects on weight gain and food and water
consumption are likely to be due to the medication itself
because no differences were detectable among the groups
before the application of the antipsychotic drugs. Compared
to control animals, rats medicated with clozapine showed a
small decrease in weight gain as well as food and water
consumption although these differences were not signifi-
cant. Rats with haloperidol medication gained less body
weight than all other groups immediately after application.
We measured significant differences in weight gain among
animals in the haloperidol group compared to controls and
animals medicated with clozapine but not in those
medicated with ziprasidone. After one week of drug
treatment, rats with haloperidol medication ate and drank
significantly less than controls and the clozapine group.
Hartfield et al.30 showed that low doses of halo-
peridol decreased drinking of a fat emulsion while cloza-
pine was associated with an increased intake. Yoshida
et al.31 observed a suppression of body weight gain in male
rats under a low oral haloperidol application that was
not accompanied by changes in food consumption but
by reduced water intake. In contrast, Minet-Ringuet
et al.32 found no differences in body weight, body composi-
tion, and food consumption among animals treated with a
lower dose of haloperidol and controls. Lee et al.33 also
observed small changes in food or water consumption at
low doses of haloperidol and clozapine. Thus, we conclude
that our observed sharp effects of haloperidol on weight
gain and food and water consumption are due to the high
drug dose applied (3.5 ¡ 0.03 mg/ kg BW). We have not
observed vacuous chewing movements following the dose
of haloperidol used in the present study, so it is unlikely
that the decreased food and water consumption among rats
under the haloperidol application was due to a malfunction
of the mandible. However, Sanci et al.34 found significantly
increased vacuous chewing movements in haloperidol-
medicated rats (1.5 mg/kg i.p.), suggesting D1 receptor
stimulation and possibly receptor supersensitivity.
After three weeks of ziprasidone medication, rats
showed a significant decrease in weight gain compared to
controls, but there was no statistical difference compared to
the clozapine or haloperidol groups over the whole
experiment period. Food consumption was significantly
reduced in comparison to the controls after two weeks of
drug treatment, and water consumption decreased after
one week in comparison to the control and clozapine
groups. Therefore, in contrast to the animals treated with
haloperidol, the effects on weight gain among those in
other groups were possibly caused by decreased food
consumption.
As described by Davoodi et al.35 and Fell et al.,36
ziprasidone intake is not associated with weight gain and
hyperphagia in either humans or rodents. Although
ziprasidone is an atypical antipsychotic drug, its effects on
weight gain and food and water consumption show a delay
in time comparable to that seen with the use of the typical
antipsychotic haloperidol. Terry et al.37 reported that in rats,
ziprasidone has less pronounced behavioral effects, and
neurochemical deficits appear to be more delayed.
Figure 6 - Serum leptin level of male Wistar rats after 2, 4, and 6 weeks of antipsychotic drug application and serum level of haloperidol
and clozapine: control (n = 19) and animals treated with haloperidol, clozapine, or ziprasidone (n = 20 for all groups). Serum levels of
leptin increased over time in the control, clozapine, and ziprasidone groups, whereas the haloperidol-medicated group showed a
maximum increase after 4 weeks of drug application. But significant differences of serum leptin levels were found after only 2 weeks of
medication between the clozapine and ziprasidone groups with p # 0.016. After 6 weeks, the level of N-desmethyl clozapine in the
serum is 10 times higher than the level of clozapine.
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Mechanisms underlying drinking behavior remain
unclear. There is some evidence that nitric oxide plays a
role in the regulation of drinking.38 Studies have shown that
the brain’s L-arginine/NO pathway may be involved in the
central effect of leptin on feeding behavior and body weight
gain in mice38 and chickens.40 These mechanisms must be
substantiated by further investigations.
We found a positive correlation for all 4 groups between
food intake and body weight before blood sampling. Only
the animals medicated with haloperidol showed a positive
correlation between body weight and serum leptin levels
after 6 weeks of drug application. While our data do not
exclude the possibility that a chronic application of
haloperidol might have a decreasing impact on number,
size, or leptin secretion rate of adipocytes proportional to
the body weight, it must be noted that Minet-Ringuet et
al.41 did not observe any effects of haloperidol on cell size,
lipolytic activity, and glucose transport activity in rat
adipocytes after oral treatment for five weeks.
Horizontal locomotor activity and alcove test
In the alcove test, which assesses fear and anxiety, we
found no differences among animals in the four groups. Rats
with haloperidol medication showed a highly significant
decrease in locomotor activity compared to those in the other
groups. Interestingly, there was a habituation effect over time
in controls and in rats medicated with clozapine and ziprasi-
done, while the low activity counts of the rats in the halo-
peridol group remained unchanged over the test period. This
corroborates earlier studies31,42,43 showing a reduced
activity under haloperidol application closely related to
the mesolimbic and mesocortical nervous system. Sorge44
also showed that clozapine had no effect on the spontaneous
locomotor activity of rats.
Antagonistic blockade of dopamine D2 receptors using
haloperidol led to a suppression of locomotor activity in rats
by decreasing the excitability of the spinal motor centers.45
The study of Huang et al.46 found that locomotion and
appetitive behavior are differently sensitive to haloperidol,
which allows the suggestion that separable D2 mechanisms
are involved in regulating the feeding behavior. Nitric oxide
seems to play a role not only in drinking regulation but also in
motor behavior, probably due to interference with dopami-
nergic neurotransmission.47 Decreased water consumption
can cause tiredness, obnubilation, and apathy in humans.
Both systems and their interaction may explain the very low
activity level in male rats under haloperidol medication. The
reduced activity under haloperidol was not solely induced by
a dysfunction of water balance – in animals treated with
ziprasidone there was reduced water consumption, but no
decreased locomotor activity was detectable despite the high
affinity of this drug to bind to dopamine D2 and D3 receptors.
Serum leptin level and receptor expression in the
hypothalamus
Clozapine and olanzapine seem to cause the greatest risk
of weight gain for respectively treated patients, whereas
ziprasidone or haloperidol generally account for no or
minimal increase in weight.48 As shown by Atmaca et al.,4
leptin is involved in the regulation of body weight, and its
concentration in blood seems to be increased under
clozapine medication. However, Haupt et al.17 found no
differences in plasma leptin concentrations calculated
separately according to gender and concluded that the
increased weight under antipsychotic medication was not
correlated with a malfunctioning leptin secretion or sensi-
tivity, respectively. Kraus et al.49 measured lower leptin
levels in schizophrenics compared to depressive patients.
He found that the decreased leptin concentration was
independent of drug medication.
Our results showing a lower serum leptin level after a 6-
week treatment with haloperidol were similar to the
findings of Minet-Ringuet et al.32 Except for the clozapine
and ziprasidone groups at the time of the first blood
sampling after 2 weeks of drug application, we found no
changes in the leptin blood concentration among the four
groups of animals, although animals medicated with
haloperidol exhibited decreased body weight. Therefore,
we conclude that the drugs have no effect on the leptin
secretion of the adipocytes. We had the same results as
Hauner et al.,50 finding no in vitro effect of clozapine on
leptin expression and its release from the adipocytes. In line
with these findings, Minet-Ringuet et al.41 reported that
haloperidol had no effect on cell size, lipolytic activity, and
glucose transport activity in rat adipocytes after a five-week
oral treatment.
Animal models do not always mimic clinical findings but
can help researchers understand underlying mechanisms.
Due to metabolic differences between humans and rodents,
our model naturally has its limits. One of them is the finding
of the applied drugs having no effect on serum leptin levels
in male Wistar rats, which seem to be less sensitive to drug-
induced metabolic changes than Sprague Dawley32 or Han
Wistar rats.21 Both of the named rat strains showed drug-
induced differences in serum leptin levels.
Because we lacked specifications, we chose drug doses
corresponding to the results of the preliminary dose test.
Jennings et al.51 showed that the increased c-Fos expression
in the rat brain induced by oral administration of 10 mg/ kg
ziprasidone may be consistent with reported clinical effects.
In human patients, the chosen dose of ziprasidone is
normally 10 times higher than the haloperidol dose.
However, lacking data on the antipsychotic efficacy in our
rat model is a strong limitation of our study. Furthermore,
our treatment period may have been too short to show
significant alterations in leptin levels, and studies using
long-term treatment are recommended.
Leptin plays a significant role in energy homeostasis.52 It
signals the status of fat stores to the hypothalamus and
interacts with orexigenic and anorexigenic central path-
ways. Strong receptor expression was demonstrated in
regions of the hypothalamus.53 Leptin receptors expressed
in hypothalamic areas process the intensity of the leptin
signal and effector systems, including the sympathetic
nervous system, and supervise energy intake and expendi-
ture.
Although food and water consumption was significantly
decreased in rats medicated with haloperidol and ziprasi-
done compared to controls, we found no changes in
hypothalamic leptin receptor expression, even after pro-
longed antipsychotic drug medication. Liu et al.54 found
that the blood concentration of leptin in obese rats was
increased and that gene expression levels of Ob-Ra and Ob-
Rb in the hypothalamus were significantly reduced. Leptin
blood concentration in obese rats had a significant negative
association with both Ob-Ra and Ob-Rb gene expression
levels in the hypothalamus, and this suggests that a leptin
mediated down-regulation of Ob-R expression is one of the
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leptin-resistant mechanisms for maintaining obesity. In
summary, the results of our study suggest that the atypical
antipsychotic drugs clozapine and ziprasidone do not
influence the peripheral and central pathway of leptin in
Wistar rats. It is plausible that these drugs have a direct
effect on the rat brain, especially mediated by NPY-
containing neurons of the hypothalamus.55 Oral antipsy-
chotic treatment with these drugs did not cause weight gain
in male rats. This finding is concordant with the results of
Baptista et al. 55 who found no conclusive evidence that
leptin was involved in inducing obesity in patients after
atypical antipsychotic drug medication.
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